H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 29.75 DKK -1.16%
Market Cap: 29.6B DKK

Relative Value

The Relative Value of one HLUN A stock under the Base Case scenario is hidden DKK. Compared to the current market price of 29.75 DKK, H Lundbeck A/S is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HLUN A Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
50
vs Industry
61
Median 3Y
1.3
Median 5Y
1.3
Industry
2.6
Forward
1.2
vs History
50
vs Industry
38
Median 3Y
9
Median 5Y
9
Industry
21.5
vs History
7
vs Industry
39
Median 3Y
5.5
Median 5Y
5.5
Industry
16.6
vs History
47
vs Industry
36
Median 3Y
2.1
Median 5Y
2.1
Industry
24
vs History
68
vs Industry
53
Median 3Y
1.3
Median 5Y
1.3
Industry
2.1
vs History
13
vs Industry
50
Median 3Y
1.4
Median 5Y
1.4
Industry
2.7
Forward
1.7
vs History
13
vs Industry
65
Median 3Y
1.8
Median 5Y
1.8
Industry
5.3
vs History
26
vs Industry
40
Median 3Y
6
Median 5Y
6
Industry
12.8
Forward
6.6
vs History
34
vs Industry
37
Median 3Y
7.6
Median 5Y
7.6
Industry
16.2
vs History
5
vs Industry
31
Median 3Y
5.4
Median 5Y
5.4
Industry
14.9
vs History
7
vs Industry
25
Median 3Y
6.2
Median 5Y
6.2
Industry
17.7
vs History
68
vs Industry
60
Median 3Y
1
Median 5Y
1
Industry
1.9

Multiples Across Competitors

HLUN A Competitors Multiples
H Lundbeck A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
H Lundbeck A/S
CSE:HLUN A
29.5B DKK 1.3 9 7.9 7.9
US
Eli Lilly and Co
NYSE:LLY
744B USD 15.2 67 36 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
362.6B USD 4.1 16.6 12.2 16
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 7.2 20.7 14.3 16.4
CH
Roche Holding AG
SIX:ROG
206.8B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
186.5B CHF 4.3 17.8 10.5 14
UK
AstraZeneca PLC
LSE:AZN
163.6B GBP 4 28.4 130.8 197.3
US
Merck & Co Inc
NYSE:MRK
199.5B USD 3.1 11.4 8.5 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
135.8B USD 2.2 17.2 7.4 10.4
P/E Multiple
Earnings Growth PEG
DK
H Lundbeck A/S
CSE:HLUN A
Average P/E: 23.7
9
21%
0.4
US
Eli Lilly and Co
NYSE:LLY
67
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.6
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.7
18%
1.2
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.4
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.4
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.2
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBITDA: 395
7.9
4%
2
US
Eli Lilly and Co
NYSE:LLY
36
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
14.3
13%
1.1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
10.5
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
130.8
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.5
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
2%
3.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBIT: 1 698.2
7.9
4%
2
US
Eli Lilly and Co
NYSE:LLY
39.3
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
16.4
14%
1.2
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.3
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.3
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
10%
1